Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Operating Expenses (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Operating Expenses for 10 consecutive years, with $5.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses fell 9.54% to $5.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $60.8 million, a 105.27% increase, with the full-year FY2024 number at $65.1 million, up 300.05% from a year prior.
  • Operating Expenses was $5.5 million for Q3 2025 at Rein Therapeutics, down from $6.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $42.8 million in Q4 2024 to a low of $2.0 million in Q3 2023.
  • A 5-year average of $8.1 million and a median of $6.8 million in 2021 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: crashed 75.23% in 2023, then surged 487.06% in 2024.
  • Rein Therapeutics' Operating Expenses stood at $6.8 million in 2021, then plummeted by 31.0% to $4.7 million in 2022, then surged by 55.01% to $7.3 million in 2023, then soared by 487.06% to $42.8 million in 2024, then plummeted by 87.17% to $5.5 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Operating Expenses are $5.5 million (Q3 2025), $6.9 million (Q2 2025), and $5.6 million (Q1 2025).